EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The rising SARS‐CoV‐2 JN.1 variant: evolution, infectivity, immune escape, and response strategies

Yishan Lu iD, Danyi Ao iD, Xuemei He, Xiawei Wei iD

MedComm · 2024-08 · 5 (8)

DOI: 10.1002/mco2.675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm, online erschienen am 29.07.2024. Verfasst von Yishan Lu und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy West China Hospital Sichuan University Sichuan People's Republic of China. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The JN.1 variant of COVID‐19 has emerged as the dominant strain worldwide since the end of 2023. As a subclade of the BA.2.86 variant, JN.1 harbors a unique combination of mutations inherited from the BA.2.86 lineage, notably featuring the novel L455S mutation within its receptor‐binding motif. This mutation has been linked to increased transmissibility and enhanced immune evasion capabilities. During the rise of JN.1, evidence of resistance to various monoclonal antibodies and reduced cross‐neutralization effects of the XBB.1.5 vaccine have been observed. Although the public health threat posed by the JN.1 variant appears relatively low, concerns persist regarding its evolutionary trajectory under immune pressure. This review provides a comprehensive overview of the evolving JN.1 variant, highlighting the need for continuous monitoring and investigation of new variants that could lead to widespread infection. It assesses the efficacy of current vaccines and therapeutics against emerging variants, particularly focusing on immunocompromised populations. Additionally, this review summarizes potential vaccine advancements and clinical treatments for COVID‐19, offering insights to optimize prevention and treatment strategies. This review thoroughly evaluates the JN.1 variant's impact on public health and its implications for future vaccine and therapeutic development, contributing to ongoing efforts to mitigate the risk of virus transmission and disease severity.

Schlagwörter

Stichwörter der Autor:innen

JN.1 variantimmune evasionresponse strategiesvaccine

Autor:innen und Institutionen

  • State Key Laboratory of Biotherapy West China Hospital Sichuan University Sichuan People's Republic of China.

ORCID-Profile: Yishan Lu, Danyi Ao, Xiawei Wei

Zitieren

APA

Lu, Y., Ao, D., He, X., & Wei, X. (2024). The rising SARS‐CoV‐2 JN.1 variant: evolution, infectivity, immune escape, and response strategies. MedComm, 5(8). https://doi.org/10.1002/mco2.675

Vancouver

Lu Y, Ao D, He X, Wei X. The rising SARS‐CoV‐2 JN.1 variant: evolution, infectivity, immune escape, and response strategies. MedComm. 2024;5(8). doi:10.1002/mco2.675

BibTeX
@article{Lu2024,
  author = {Lu, Yishan and Ao, Danyi and He, Xuemei and Wei, Xiawei},
  title = {The rising SARS‐CoV‐2 JN.1 variant: evolution, infectivity, immune escape, and response strategies},
  journal = {MedComm},
  year = {2024},
  volume = {5},
  number = {8},
  doi = {10.1002/mco2.675}
}
Kostenlos starten →